相似文献
1
Vascular targeting of antithrombotic agents.
IUBMB Life. 2011 Aug;63(8):632-9. doi: 10.1002/iub.474. Epub 2011 Jul 15.
2
Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.
Thromb Haemost. 1995 Jul;74(1):464-72.
3
Clot-Targeted Nanogels for Dual-Delivery of AntithrombinIII and Tissue Plasminogen Activator to Mitigate Disseminated Intravascular Coagulation Complications.
ACS Nano. 2024 Jun 18;18(24):15517-15528. doi: 10.1021/acsnano.4c00162. Epub 2024 Jun 5.
4
Wall passivation for unstable angina.
Semin Interv Cardiol. 1996 Mar;1(1):60-6.
5
Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.
Heart Vessels. 1996;11(3):133-44. doi: 10.1007/BF01745171.
6
Improved microvessel repair: laser welding with an anti-thrombotic solder.
Lasers Surg Med. 2002;31(1):36-40. doi: 10.1002/lsm.10071.
7
[Anticoagulants. Various developmental starting points on direct antithrombins as antithrombotic agents].
Thromb Diath Haemorrh Suppl. 1973;55:179-97.
8
Antithrombotic effect of synthetic thrombin inhibitors.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;98(4):483-7.
9
Combination targeting of 'platelets + fibrin' enhances clot anchorage efficiency of nanoparticles for vascular drug delivery.
Nanoscale. 2020 Nov 7;12(41):21255-21270. doi: 10.1039/d0nr03633a. Epub 2020 Oct 16.
10
Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Thromb Haemost. 1997 Jul;78(1):736-41.
引用本文的文献
1
Fibrin-specific poly(N-isopropylacrylamide) nanogels for targeted delivery of tissue-type plasminogen activator to treat thrombotic complications are well tolerated in vivo.
Bioeng Transl Med. 2021 Dec 11;7(2):e10277. doi: 10.1002/btm2.10277. eCollection 2022 May.
2
Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Mol Pharm. 2017 Nov 6;14(11):3815-3823. doi: 10.1021/acs.molpharmaceut.7b00559. Epub 2017 Sep 26.
3
Mechanism of Collaborative Enhancement of Binding of Paired Antibodies to Distinct Epitopes of Platelet Endothelial Cell Adhesion Molecule-1.
PLoS One. 2017 Jan 13;12(1):e0169537. doi: 10.1371/journal.pone.0169537. eCollection 2017.
4
Advanced drug delivery systems for antithrombotic agents.
Blood. 2013 Aug 29;122(9):1565-75. doi: 10.1182/blood-2013-03-453498. Epub 2013 Jun 24.
本文引用的文献
1
Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.
Pediatr Crit Care Med. 2011 Nov;12(6):e369-75. doi: 10.1097/PCC.0b013e3181fe40a7.
2
Targeting antioxidant and antithrombotic biotherapeutics to endothelium.
Semin Thromb Hemost. 2010 Apr;36(3):332-42. doi: 10.1055/s-0030-1253455. Epub 2010 May 20.
3
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
Blood. 2010 Jun 24;115(25):5241-8. doi: 10.1182/blood-2010-01-261610. Epub 2010 Apr 21.
4
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.
J Pharmacol Exp Ther. 2010 Mar;332(3):1022-31. doi: 10.1124/jpet.109.159194. Epub 2009 Dec 1.
5
The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator.
Biomaterials. 2009 Oct;30(29):5751-6. doi: 10.1016/j.biomaterials.2009.07.021. Epub 2009 Aug 4.
6
Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.
J Control Release. 2009 Nov 3;139(3):190-6. doi: 10.1016/j.jconrel.2009.07.003. Epub 2009 Jul 16.
7
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation.
J Cereb Blood Flow Metab. 2009 Aug;29(8):1463-74. doi: 10.1038/jcbfm.2009.61. Epub 2009 May 13.
8
Targeted delivery of thrombolytic agents: role of integrin receptors.
Expert Opin Drug Deliv. 2009 May;6(5):499-508. doi: 10.1517/17425240902878002.
9
Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.
J Neurotrauma. 2009 Sep;26(9):1585-92. doi: 10.1089/neu.2008.0720.
10
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator.
Circulation. 2008 Sep 30;118(14):1442-9. doi: 10.1161/CIRCULATIONAHA.107.750257. Epub 2008 Sep 15.
Zotero 插件